Clinical outcome of Simeprevir Plus Sofosbuvir Regimen in Comparison to Daclatasvir Plus Sofosbuvir Regimen for Treatment of Chronic Hepatitis C Egyptian Cirrhotic and Non-cirrhotic Patients

Abstract

Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) which mainly attacks the liver cells. Near eighty percent of patients develop CHC that after many years may lead to cirrhosis or liver cancer. Egypt has the highest prevalence rate of HCV in the world. About 14.7% of the Egyptian people have HCV antibodies and 9.8% have an active infection. In Egypt, The death rate due to liver disease about 40,000 each year (near 10% of all deaths). It is the second after the cardiac diseases. With the ultimate goal of achieving a more potent strategy to control transmission of HCV in Egypt, The Ministry of Health has set up 32 specialized centers for the nationwide therapy of HCV ‎infection. Standard treatment for chronic hepatitis C infection was pegylated-interferon (Peg IFN) and ribavirin (RBV). New era for management of chronic HCV using direct antiviral agents (DAAs) started in 2013.